DKN-01 with bevacizumab and chemotherapy in advanced CRC

(32)

Bevacizumab and colorectal cancer in geriatrics

(5:34)

Upfront Bevacizumab and Cetuximab Compared in Metastatic Colorectal Cancer

(4:56)

Dr. Horn on the FDA Approval of Atezolizumab Plus Bevacizumab and Chemotherapy in NSCLC

(1:8)

EMERALD-1: durvalumab, bevacizumab and TACE in unresectable HCC

(1:34)

Bevacizumab and cetuximab (plus chemotherapy) equally effective for colorectal cancer patients

(11:15)

BEAT-meso: Phase III trial of bevacizumab and chemo ± atezolizumab for advanced pleural mesothelioma

(40)

Bevacizumab and cetuximab (plus chemotherapy) equally effective for colorectal cancer patients

(9:2)

ASCO 2009: Bevacizumab and standard adjuvant chemotherapy

(8:5)

Personal Experience with Bevacizumab

(4:1econd)

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy ...

(6:36)

Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC

(2:40)

Bevacizumab and Interferon in mRCC

(3:16)

Dr. Dowdy on Bevacizumab and Improvement of PFS in Ovarian Cancer

(1:5)

Comment: Impact of combined bevacizumab and presurgery chemo varies by subtype

(1:54)

CeLEBrATE: carboplatin, etoposide, bevacizumab and atezolizumab in extensive-stage SCLC

(54)

Dr. Jason A. Konner on Bevacizumab in Advanced Ovarian Cancer

(2:18)

Phase III EMERALD-1: bevacizumab and durvalumab with TACE improves PFS in unresectable HCC

(1:3)

FFCD 1709-SIRTCI: selective internal radiation therapy + xelox, bevacizumab and atezolizumab in mCRC

(59)

Assessing the Use of Bevacizumab

(4:12)